Background: Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first-line treatment for moderate and severe pemphigus vulgaris in Europe and the United States. Objectives: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated a throughout update of the guideline for the management of patients with pemphigus. Results: The guidelines for the management of pemphigus were updated, and the degree of consent among all task force members was included. The final version of the guideline was consented by the European Dermatology Forum (EDF) and several patient organizations.

Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV) / Joly, P.; Horvath, B.; Patsatsi, Alpha.; Uzun, S.; Bech, R.; Beissert, S.; Bergman, R.; Bernard, P.; Borradori, L.; Caproni, M.; Caux, F.; Cianchini, G.; Daneshpazhooh, M.; De, D.; Dmochowski, M.; Drenovska, K.; Ehrchen, J.; Feliciani, C.; Goebeler, M.; Groves, R.; Guenther, C.; Hofmann, S.; Ioannides, D.; Kowalewski, C.; Ludwig, R.; Lim, Y. L.; Marinovic, B.; Marzano, A. V.; Mascaro, J. M.; Mimouni, D.; Murrell, D. F.; Pincelli, C.; Squarcioni, C. P.; Sardy, M.; Setterfield, J.; Sprecher, E.; Vassileva, S.; Wozniak, K.; Yayli, S.; Zambruno, G.; Zillikens, D.; Hertl, M.; Schmidt, E.. - In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. - ISSN 0926-9959. - 34:9(2020), pp. 1900-1913. [10.1111/jdv.16752]

Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)

Feliciani C.
Supervision
;
2020-01-01

Abstract

Background: Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first-line treatment for moderate and severe pemphigus vulgaris in Europe and the United States. Objectives: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated a throughout update of the guideline for the management of patients with pemphigus. Results: The guidelines for the management of pemphigus were updated, and the degree of consent among all task force members was included. The final version of the guideline was consented by the European Dermatology Forum (EDF) and several patient organizations.
2020
Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV) / Joly, P.; Horvath, B.; Patsatsi, Alpha.; Uzun, S.; Bech, R.; Beissert, S.; Bergman, R.; Bernard, P.; Borradori, L.; Caproni, M.; Caux, F.; Cianchini, G.; Daneshpazhooh, M.; De, D.; Dmochowski, M.; Drenovska, K.; Ehrchen, J.; Feliciani, C.; Goebeler, M.; Groves, R.; Guenther, C.; Hofmann, S.; Ioannides, D.; Kowalewski, C.; Ludwig, R.; Lim, Y. L.; Marinovic, B.; Marzano, A. V.; Mascaro, J. M.; Mimouni, D.; Murrell, D. F.; Pincelli, C.; Squarcioni, C. P.; Sardy, M.; Setterfield, J.; Sprecher, E.; Vassileva, S.; Wozniak, K.; Yayli, S.; Zambruno, G.; Zillikens, D.; Hertl, M.; Schmidt, E.. - In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. - ISSN 0926-9959. - 34:9(2020), pp. 1900-1913. [10.1111/jdv.16752]
File in questo prodotto:
File Dimensione Formato  
Acad Dermatol Venereol - 2020 - Joly - Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus.pdf

non disponibili

Tipologia: Versione (PDF) editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 755.96 kB
Formato Adobe PDF
755.96 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2880638
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 176
  • ???jsp.display-item.citation.isi??? 148
social impact